Live Online Training: Design Controls for Drug - Device Combination Products

Live Online Training: Design Controls for Drug - Device Combination Products

Course No 18381

Note: All times mentioned are CEST.

Costs

ECA-Member: EUR 1690,--
Non ECA Member: EUR 1890,--
EU/GMP Inspectorates: EUR 945,--
APIC Member Discount: EUR 1790,--

(All prices excl. VAT)

If you have any questions, please contact us:
Tel.: +49 (0)6221 / 84 44 0 E-Mail: info@gmp-compliance.org

Speakers

Ilanit Goldgraber, West Pharma, Israel
Torsten Kneuss, Bayer, Germany
Horst Koller, HK Packaging, Switzerland
Paolo Mazzoni, PTM Consulting, Italy
Lee Wood, medHF, Switzerland

Objectives

This Live Online Training provides a comprehensive overview of the technical and regulatory requirements for the development and maintenance of drug-device combination products (with a focus on EU & US).

Participants will learn and understand
  • the basics – distinctions between drugs, devices and ‘combination products’,
  • the current applicable regulations, standards and guidelines related to the design and development of combination products and how to be compliant with those requirements
  • the key elements of Design Controls, Risk Management and Usability Engineering.
Case Studies are an integral part of the course Programme.

Background

More than half of the TOP20 drug products on the market include at least one device constituent part and are therefore considered Drug-device combination products. Drug-Device combination products are specifically regulated in the US. However, there is also an increasing oversight by regulatory authorities in the EU. Compliant development and life-cycle management are, therefore, essential for obtaining and maintain a marketing authorization for such products.

What is a Combination Product?

“Combination Product”, as per 21 CFR Part 3.2(e), is a term defined by the FDA to cover products which consist of two or more components (i.e., drug, biologic, device) regulated under different regulations. The FDA differentiates between three basic types of combination products:
  • Single-entity combination products,
  • Co-packaged combination products,
  • Cross-labeled combination products.
Beyond these basic types also combinations of those basic types are possible.

During the past years, FDA established regulations and guidances for Combination Products, which further clarify what Combination Products are and which rules apply to such combinations.

21 CFR Part 4, along with the final guidance “Current Good Manufacturing Practice (cGMP) Requirements for Combination Products”, provides guidance on applicable quality requirements for combination products.

One essential requirement is to apply Design Controls as defined in 21 CFR Part 820.30 to the combination product as a whole. Design Controls are a set of quality practices and procedures to control the design process to assure that the combination product meets the user needs, intended uses and specified requirements. Design Controls support a systematic design and development process and ensure that the product fulfils those requirements which have been defined at the beginning of the project and that the final product fulfils the purpose. Design Controls are described in ISO 13485 (applicable for Medical Devices), in ISO 15378 (applicable to primary packaging materials) and even in the general standard for quality management system ISO 9001.

In the EU, so far, there has been no equivalent term to “Combination Product”, a product is either considered a Medical Device or a Medicinal Product. Medical devices have to comply currently with the Medical Device Directive and shortly with the EU Medical Device Regulation (MDR). Even though the term Combination Product does not exist, also in EU, the Design Controls apply to the so-called single-integral products, which are similar to single-entity combination products as defined in the US.

Also shared in EU and US is the requirement to apply Risk Management to those products. The respective standard ISO 14971 has been revised in 2019. The course will consider the recent changes and provides guidance on how to apply Risk Management to drug-device combination products.
And lastly, also Usability Engineering, also known as Human Factors Engineering, needs to be considered in the Design and Development of combination products. The recent increase in attention to this topic has brought many manufacturers into difficulties as they aim to prove high levels of intuitive use, use safety and efficacy of the drug delivery system as a whole - for a Combination Product it is no longer just about the drug. Again, regulation, directives, guidance, standards and review expectations continue to evolve in this area.

This Live Online Training focuses on design controls as applicable to various combinations of drugs and biologics with devices. The course intends to set a solid basic understanding of the application on Design Controls as  well as on the topics of Risk Management and Usability Engineering. Beyond the basic understanding, the course also aims to offer some practical experiences with the different elements to be considered.

Target Group

This Live Online Training is designed for all scientists, engineers, managers and executives from Pharmaceutical and Biotech Development Units, including Device Development, Packaging Development, Quality Assurance, Regulatory Affairs, Marketing, and Project Management, who are involved in the development, industrialization and control of Drug-Device Combination Products.

Technical Requirements

For our webinars, we use Cisco WebEx, one of the leading suppliers of online meetings. At https://www.webex.com/test-meeting.html you can check if your system meets the necessary requirements for the participation at a WebEx meeting and at the same time install the necessary plug-in. Please just enter your name and email address for the test. If the installation is not possible because of your rights for the computer system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.

Programme

Programme Day 1
 
09.00 - 09.15 h   Welcome / Introduction
 
09.15 - 09.45 h
Regulatory Background
  • Why do we need Design Controls for medical devices and combination products?
  • Requirements in EU vs. US regarding the scope of Design Controls
  • Requirements in EU for legal manufacturer vs. requirements in US for MAH
  • Relevant standards in EU, US
09.45 - 10.30 h
Design Controls – An Introduction
  • Purpose of Design Controls / usability engineering / risk management
  • Drug development vs. device development vs. combination product development
  • Development vs. transfer vs. industrialization
  • Processes required
10.30 - 10.45 h   Coffee Break
 
10.45 - 11.15 h
Design and Development Planning
  • Definition of development scope
  • Target product profile - How to determine the scope?
  • Design reviews
11.15 - 12.00 h
Introduction to Usability Engineering
  • IEC 62366-1
  • How to determine user needs, user preference, use specification etc.
12.00 - 12.30 h
Q&A Session 1
 
12.30 - 13.30 h   Lunch Break
 
13.30 - 14.00 h
Requirements for Single-Integral Products in EU
  • How to demonstrate conformance with Annex I?
  • Setup of technical documentation
  • General safety & performance requirements
14.00 - 15.45 h
Risk Management (with Coffee Break from 14.45 - 15.00 h)
  • ISO 14971: Terms/definition, process
  • Determine known use problems
  • How to determine risk mitigations for design inputs
  • Update of risk management during development
  • Documentation of RM activities / RMF
  • Preparation of post-market surveillance / PMS planning
15.45 - 16.15 h
Design Controls for Combination Products vs. Externally Developed Device Constituents
  • How to link external development (of device constituent) with internal development of whole combination product
  • Quality oversight approaches
16.15 - 16.45 h
Design Controls and further Quality System Elements
  • Procedures needed from Design Control perspective
  • Other quality elements for combination products
16.45 - 17.15 h
Q&A Session 2
 
 
Programme Day 2
 
08.30 - 09.30 h
Design Input
  • From user needs and other stakeholder needs to design input
  • How to integrate results from UE, RM
  • How to ensure „open-ended“ development
  • Requirements for engineering techniques
09.30 - 10.30 h
Design Output
  • Development activities
  • Definition of design outputs (Specifications)
10.30 - 10.45 h   Coffee Break
 
10.45 - 11.45 h
Design Verification
  • Design verification activities
  • How to consider verification during design input
  • What to do if verification Fails?
11.45 - 12.15 h
Q&A Session 3
 
12.15 - 13.15 h   Lunch Break
 
13.15 - 14.15 h
Design Validation / Usability Engineering Part 2
  • Design validation approaches
  • Planning, Setup and conduct of summative studies
  • Documentation of the UE activities / UEF HF/UE Report as required by FDA
14.15 - 14.45 h
Design Transfer
  • Design Transfer - Why and how?
  • DMR setup
14.45 - 15.00 h   Coffee Break
 
15.00 - 16.30 h
Case Studies:
  • Pre-Filled syringes
  • Autoinjector development (Some considerations when utilising syringes in auto-injectors)
16.30 - 17.00 h
Q&A Session 4

Go back

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information

OK